reports
Bavarian Nordic iværksætter nyt langsigtet incitamentsprogram for konc...
Bavarian Nordic iværksætter nyt langsigtet incitamentsprogram for koncernledelsen og udvalgte medarbejdere KØBENHAVN, Danmark, 18. december 2025 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at bestyrelsen har besluttet at etablere et nyt langsigtet incitamentsprogram for koncernledelsen som en del af den årlige aflønning i overensstemmelse med vederlagspolitikken, som er vedtaget på generalforsamlingen. Medlemmer af koncernledelsen tildeles performancebaserede betingede aktier, der er baseret på succesfuld opnåelse af relevante Key Performance Indicators (KPI’er), målt over en treårig...
Bavarian Nordic Establishes Long-term Incentive Program for Members of...
Bavarian Nordic Establishes Long-term Incentive Program for Members of Executive Management and Selected Employees COPENHAGEN, Denmark, December 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Board of Directors has decided to establish a long-term incentive program for Executive Management as part of the annual remuneration as laid out in the Remuneration Policy, adopted at the annual general meeting. Members of the Executive Management are granted performance restricted stock units (Performance RSUs), subject to the successful achievement of relevant Key Performance In...
Bavarian Nordic vil foretage aktietilbagekøb for op til DKK 500 mio.
Bavarian Nordic vil foretage aktietilbagekøb for op til DKK 500 mio. KØBENHAVN, Danmark, 2. december 2025 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag sin hensigt om at iværksætte et engangsprogram for tilbagekøb af egne aktier for op til DKK 500 mio., som skal gennemføres over de næste 12 måneder. Denne beslutning skal ses i lyset af en nuværende stærk likviditetsposition, som følge af det nylige salg af Priority Review Voucher og en fortsat positiv pengestrøm fra driften. Pr. 30. september 2025 udgjorde værdipapirer, kontanter og likvide midler DKK 2.978 mio., hvoraf cirka DKK 800 mi...
Bavarian Nordic to Launch Share Buy-back Program of up to DKK 500 Mill...
Bavarian Nordic to Launch Share Buy-back Program of up to DKK 500 Million COPENHAGEN, Denmark, December 2, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced its intent to launch a one-time share buy-back program of up to DKK 500 million to be executed over the next 12 months. This decision should be viewed in the context of a current strong cash position, resulting from the recent sale of the Priority Review Voucher and a continued positive cash flow from operations. As of September 30, 2025, securities, cash and cash equivalents were DKK 2,978 million, of which approximately DKK 800 ...
Bavarian Nordic offentliggør delårsregnskab for de første ni måneder a...
Bavarian Nordic offentliggør delårsregnskab for de første ni måneder af 2025 KØBENHAVN, Danmark, 14. november 2025 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag regnskab for de første ni måneder af 2025 samt rapporterede på begivenheder for tredje kvartal 2025. Omsætningen i de første ni måneder steg med 32% til DKK 4.793 mio., hvilket afspejler en stærk udvikling i både Travel Health og Public Preparedness. Travel Health omsætning steg med 23% til DKK 2.327 mio. sammenlignet med de første ni måneder af 2024, hvilket primært var drevet af øget efterspørgsel på vacciner mod rabie...
Bavarian Nordic Announces Interim Results for the First Nine Months of...
Bavarian Nordic Announces Interim Results for the First Nine Months of 2025 COPENHAGEN, Denmark, November 14, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2025 and business progress for the third quarter of 2025. Revenue for the first nine months increased by 32% to DKK 4,793 million, reflecting a strong performance in both Travel Health and Public Preparedness. Travel Health revenue increased by 23% to DKK 2,327 million compared to the first nine months of 2024, primarily driven by increased demand for rabies and tick-b...
Bavarian Nordic offentliggør ændringer i bestyrelsen
Bavarian Nordic offentliggør ændringer i bestyrelsen KØBENHAVN, Danmark, 13. november 2025 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag, at formand for bestyrelsen, Luc Debruyne har besluttet at træde tilbage fra bestyrelsen med øjeblikkelig virkning. Bestyrelsen har udnævnt næstformand Anne Louise Eberhard som ny formand for bestyrelsen. “Efter nøje refleksion over både processen og resultatet af det nylige overtagelsesforsøg har jeg besluttet at træde tilbage for at give Bavarian Nordics bestyrelse mulighed for at fokusere på virksomhedens næste udviklingsfase. Jeg har stor b...
Bavarian Nordic Announces Changes to the Board of Directors
Bavarian Nordic Announces Changes to the Board of Directors COPENHAGEN, Denmark, November 13, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Chair of the Board, Luc Debruyne has decided to step down from the board with immediate effect. The Board has appointed Vice Chair Anne Louise Eberhard as new Chair of the Board. “After careful reflection on both the process and the outcome of the recent takeover attempt, I have decided to step down to enable the board of Bavarian Nordic to focus on the company’s next phase of development. I have deep appreciation for the company’s rema...
Bavarian Nordic offentliggør storaktionærmeddelelse fra Morgan Stanley
Bavarian Nordic offentliggør storaktionærmeddelelse fra Morgan Stanley KØBENHAVN, Danmark, 10. november 2025 – I henhold til §30 i Lov om kapitalmarkeder, meddeler Bavarian Nordic A/S hermed, at selskabet har modtaget meddelelse fra Morgan Stanley om, at de pr. 4. november 2025 besidder 4,94% af aktierne og stemmerettighederne i Bavarian Nordic A/S. Om Bavarian NordicBavarian Nordic er et globalt vaccineselskab med en mission om at forbedre sundheden og redde liv gennem innovative vacciner. Vi er en foretrukken leverandør af mpox- og koppevacciner til regeringer med hensyn til at forbedre...
Bavarian Nordic Announces Major Shareholder Notification from Morgan S...
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley COPENHAGEN, Denmark, November 10, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 4,94% of the shares and voting rights in Bavarian Nordic A/S as of November 4, 2025. About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to ...
Bavarian Nordic offentliggør storaktionærmeddelelse fra Morgan Stanley
Bavarian Nordic offentliggør storaktionærmeddelelse fra Morgan Stanley KØBENHAVN, Danmark, 7. november 2025 – I henhold til §30 i Lov om kapitalmarkeder, meddeler Bavarian Nordic A/S hermed, at selskabet har modtaget meddelelse fra Morgan Stanley om, at de pr. 31. oktober 2025 besidder 5,13% af aktierne og stemmerettighederne i Bavarian Nordic A/S. Om Bavarian NordicBavarian Nordic er et globalt vaccineselskab med en mission om at forbedre sundheden og redde liv gennem innovative vacciner. Vi er en foretrukken leverandør af mpox- og koppevacciner til regeringer med hensyn til at forbedre ...
Bavarian Nordic Announces Major Shareholder Notification from Morgan S...
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley COPENHAGEN, Denmark, November 7, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 5,13% of the shares and voting rights in Bavarian Nordic A/S as of October 31, 2025. About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to e...
Konsortium bestående af Nordic Capital og Permira offentliggør det for...
Konsortium bestående af Nordic Capital og Permira offentliggør det foreløbige resultat af overtagelsestilbuddet til aktionærerne i Bavarian Nordic og at Tilbuddet tilbagekaldes og ikke vil blive gennemført MÅ IKKE UDGIVES, OFFENTLIGGØRES ELLER DISTRIBUERES, DIREKTE ELLER INDIREKTE, I ELLER TIL NOGEN JURISDIKTION, HVOR DETTE VILLE UDGØRE EN OVERTRÆDELSE AF DE RELEVANTE LOVE ELLER FORORDNINGER I DEN PÅGÆLDENDE JURISDIKTION København, Danmark, 6 november 2025 – Med henvisning til selskabsmeddelelserne af 26. august 2025 (nr. 24/2025), 29 September 2025 (nr. 27/2025), 15. oktober 2025 (nr. 31...
Consortium consisting of Nordic Capital and Permira announces prelimin...
Consortium consisting of Nordic Capital and Permira announces preliminary result of the takeover offer to shareholders of Bavarian Nordic and that the Offer is withdrawn and will not be completed NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, 6 November, 2025 – With reference to company announcements dated 26 August 2025 (no. 24/2025), 29 September 2025 (no. 27/2025), 15 October 2025 (no. 31/2025), and 21 October 2025 (n...
Bavarian Nordic offentliggør storaktionærmeddelelse fra Morgan Stanley
Bavarian Nordic offentliggør storaktionærmeddelelse fra Morgan Stanley KØBENHAVN, Danmark, 5. november 2025 – I henhold til §30 i Lov om kapitalmarkeder, meddeler Bavarian Nordic A/S hermed, at selskabet har modtaget meddelelse fra Morgan Stanley om, at de pr. 30. oktober 2025 besidder 4,92% af aktierne og stemmerettighederne i Bavarian Nordic A/S. Om Bavarian NordicBavarian Nordic er et globalt vaccineselskab med en mission om at forbedre sundheden og redde liv gennem innovative vacciner. Vi er en foretrukken leverandør af mpox- og koppevacciner til regeringer med hensyn til at forbedre ...
Bavarian Nordic Announces Major Shareholder Notification from Morgan S...
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley COPENHAGEN, Denmark, November 5, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 4.92% of the shares and voting rights in Bavarian Nordic A/S as of October 30, 2025. About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to e...
Bavarian Nordic offentliggør storaktionærmeddelelse fra Morgan Stanley
Bavarian Nordic offentliggør storaktionærmeddelelse fra Morgan Stanley KØBENHAVN, Danmark, 4. november 2025 – I henhold til §30 i Lov om kapitalmarkeder, meddeler Bavarian Nordic A/S hermed, at selskabet har modtaget meddelelse fra Morgan Stanley om, at de pr. 29. oktober 2025 besidder 5,12% af aktierne og stemmerettighederne i Bavarian Nordic A/S. Om Bavarian NordicBavarian Nordic er et globalt vaccineselskab med en mission om at forbedre sundheden og redde liv gennem innovative vacciner. Vi er en foretrukken leverandør af mpox- og koppevacciner til regeringer med hensyn til at forbedre ...
Bavarian Nordic Announces Major Shareholder Notification from Morgan S...
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley COPENHAGEN, Denmark, November 4, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 5.12% of the shares and voting rights in Bavarian Nordic A/S as of October 29, 2025. About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to e...
Bavarian Nordic offentliggør storaktionærmeddelelse fra Morgan Stanley
Bavarian Nordic offentliggør storaktionærmeddelelse fra Morgan Stanley KØBENHAVN, Danmark, 31. oktober 2025 – I henhold til §30 i Lov om kapitalmarkeder, meddeler Bavarian Nordic A/S hermed, at selskabet har modtaget meddelelse fra Morgan Stanley om, at de pr. 27. oktober 2025 besidder 4.99% af aktierne og stemmerettighederne i Bavarian Nordic A/S. Om Bavarian NordicBavarian Nordic er et globalt vaccineselskab med en mission om at forbedre sundheden og redde liv gennem innovative vacciner. Vi er en foretrukken leverandør af mpox- og koppevacciner til regeringer med hensyn til at forbedre ...
Bavarian Nordic Announces Major Shareholder Notification from Morgan S...
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley COPENHAGEN, Denmark, October 31, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 4.99% of the shares and voting rights in Bavarian Nordic A/S as of October 27, 2025. About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to en...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.